
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx Inc's total revenue surpassed consensus estimates by approximately $16 million, driven by a significant $8 million contribution from IBSRELA, leading management to revise its FY25 guidance upward by $10 million. Excluding a one-time benefit, the company demonstrated healthy 27% quarter-over-quarter growth and reiterated its peak U.S. revenue guidance of $750 million before patent expiration. Additionally, XPHOZAH's U.S. net sales exceeded estimates by around $3 million, indicating early success in the company’s strategy amidst changes in Medicare Part D coverage.
Bears say
Ardelyx Inc faces ongoing challenges with its financial outlook due to the loss of Medicare Part D coverage for its product Xphozah, which increases reliance on the non-Medicare patient population that represents only about 40% of the market. The absence of financial guidance for fiscal year 2025 contributes to a heightened sense of uncertainty regarding the company's revenue trajectory and overall financial stability. This strategic pivot, while indicative of adaptability, raises concerns over the sustainability of Ardelyx's current business model amid these constraints.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares